U.S. Machinery Stock News

Oriental Rise Holdings Limited ( NASDAQ:ORIS ) shareholders won't be pleased to see that the share price has had a very...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...

Those holding Frontier Group Holdings, Inc. ( NASDAQ:ULCC ) shares would be relieved that the share price has rebounded...

Over the past year, many Lennox International Inc. ( NYSE:LII ) insiders sold a significant stake in the company which...

The board of Bunge Global SA ( NYSE:BG ) has announced that it will pay a dividend of $0.70 per share on the 3rd of...

We can readily understand why investors are attracted to unprofitable companies. For example, VirnetX Holding...

Energy Services of America Corporation ( NASDAQ:ESOA ) shares have had a horrible month, losing 26% after a relatively...

MYR Group's (NASDAQ:MYRG) stock is up by a considerable 18% over the past three months. Given that stock prices are...

On 1 December 2025, Ramaco Resources held a special call to discuss U.S. critical mineral initiatives and the development of its Brook Mine, highlighting progress on what could become a key rare earth asset. This focus on Brook Mine and critical minerals directly connects to Ramaco’s ambitions to expand beyond metallurgical coal into federally supported rare earth production. We’ll now explore how the Brook Mine-focused critical minerals call may reshape Ramaco’s investment narrative and...

In late November 2025, Sandisk Corporation was added to multiple large-cap indices including the S&P 500, S&P 500 Information Technology, S&P 500 Equal Weighted and S&P Global 1200, while being removed from several small- and mid-cap benchmarks. This rapid index migration reflects Sandisk’s shift into the large-cap mainstream, underpinned by strong AI-driven demand for its NAND flash storage and a recent return to profitability. Next, we’ll examine how Sandisk’s S&P 500 inclusion and...

Morgan Stanley recently upgraded Bausch + Lomb to Overweight from Equal Weight, pointing to what it views as the strongest product pipeline in ophthalmology and highlighting new disruptive treatments in development. The bank also emphasized efficiency initiatives that are helping lift profit margins, suggesting the company may be entering a more productive phase for converting innovation into earnings. Next, we’ll examine how Morgan Stanley’s upbeat view on Bausch + Lomb’s disruptive...

Youdao (NYSE:DAO) just reported its third quarter 2025 results, and they are a bit of a mixed bag, with modest revenue growth for the quarter but a sharp drop in quarterly profit, alongside stronger nine-month profitability. See our latest analysis for Youdao. Despite the wobble in quarterly profit, investors seem to be looking through the noise. A solid year-to-date share price return of 34.22% and a 1-year total shareholder return of 44.78% suggest momentum is still broadly constructive,...

Savara (SVRA) has been back on traders radar after securing a European patent for its Molbreevi drug device combo, just as management heads into high profile healthcare conferences where fresh updates are expected. See our latest analysis for Savara. The stock has ridden a clear wave of renewed optimism, with a roughly 36 percent 1 month share price return and an 89 percent year to date share price gain pointing to building momentum. A 3 year total shareholder return above 260 percent...

In late November 2025, Zoom Communications Inc. reported third-quarter fiscal 2026 results showing higher sales and net income than a year earlier, raised its full-year 2026 revenue guidance to about US$4.85 billion, issued fourth-quarter revenue guidance of roughly US$1.23 billion, and disclosed completing a share repurchase of over 32.50 million shares for about US$2.38 billion. An interesting element is how Zoom combined earnings growth with a sizeable buyback, which can lift earnings per...

BILL Holdings (BILL) is heading into the UBS Global Technology and AI Conference with fresh momentum after its latest quarterly earnings cleared Wall Street expectations and helped lift the stock nearly 16% in the past month. See our latest analysis for BILL Holdings. That post earnings bounce stands in contrast to a year to date share price return of minus 40.2 percent and a one year total shareholder return of minus 43.2 percent. Recent momentum is still more of a tentative recovery than a...

Wondering if ASML Holding is still worth buying after its huge run, or if the easy money has already been made? This article will walk through what the current price is really baking in. The stock has climbed about 6.5% over the last week, 3.9% over the past month, and is up a hefty 58.3% year to date. This naturally raises questions about how much upside is left versus the risk of a pullback. Recent moves have come as investors double down on the long term demand story for advanced...

PACCAR (PCAR) has quietly outpaced the broader market over the past month, gaining about 9% while still sitting roughly 7% below its level a year ago. That mix of momentum and pullback invites a closer look at valuation. See our latest analysis for PACCAR. That recent 1 month share price return of about 8.7% suggests momentum is rebuilding after a softer year, even though the 1 year total shareholder return is still negative and lags the strong multi year record. If PACCAR’s move has you...

In late November 2025, PagerDuty reported third-quarter results showing higher sales and a move from a loss to profitability, raised its full-year 2026 earnings guidance, and later announced it had become one of the first software partners to achieve the AWS Resilience Services Competency. The combination of stronger earnings, an upgraded profit outlook, and AWS recognition for resilience services highlights how PagerDuty is tying incident management, resilience engineering and cloud...

Recently, Clover Health Investments highlighted that it expects to achieve GAAP profitability in 2026, while continuing to face pressure from higher-than-anticipated medical costs this year. The company is leaning on its Clover Assistant technology, early diagnosis initiatives, and anticipated support from CMS Part D measures to help rein in medical expenses and improve its long-term operating profile. Next, we’ll examine how the push toward GAAP profitability and broader Clover Assistant...

Wondering if AtriCure at around $35 is quietly setting up a value opportunity, or if the market already has it priced just right? You are not alone in asking whether now is the moment to pay closer attention. The stock is up 16.2% year to date and 3.8% over the last month, even though it is still slightly down over 1 year and meaningfully lower over 3 and 5 years. This pattern hints at shifting sentiment and fresh expectations. Recent headlines have focused on AtriCure's progress in cardiac...

Earlier in 2025, Liquidia Technologies reported strong third-quarter results, with its pulmonary arterial hypertension therapy Yutrepia delivering sales that surpassed market expectations. On the same day, General Counsel Russell Schundler sold shares and exercised options under a pre-set Rule 10b5-1 plan, highlighting routine insider activity alongside operational momentum. Next, we’ll explore how Yutrepia’s stronger-than-expected performance shapes Liquidia’s investment narrative despite a...

If you are wondering whether Coca-Cola FEMSA. de is still worth considering after its recent run up, or if the easy money has already been made, you are in the right place because we are going to dig into what the current share price really implies. The stock has climbed about 1.1% over the last week, 2.8% over the past month, and 14.3% year to date, building on longer term gains of 12.0% over 1 year, 45.7% over 3 years, and 135.5% over 5 years. Behind those moves, the market has been...

American Assets Trust (AAT) has been grinding through a tough stretch, with the stock down sharply this year even as revenue inches higher, making the REIT increasingly interesting for value-focused income investors. See our latest analysis for American Assets Trust. At around $19.44, American Assets Trust’s recent weakness, including a sharp year to date share price return decline, has come as investors reassess REIT risk, even though the three and five year total shareholder returns already...